Real‐world use of lecanemab: patient pathway findings from a US multicenter study

Abstract Introduction To ensure Alzheimer's disease‐modifying treatments can be initiated in diverse populations, efficient pathways to obtain timely diagnoses are required. Methods This interim sub‐analysis of a multicenter US study included cross‐sectional surveys and interviews with neurologists...

תיאור מלא

מידע ביבליוגרפי

Principais autores:	Michael Rosenbloom, Courtney Adams, Brooke Allen, Brent Berry, Christian Camargo, Gregory Cooper, Samuel Giles, Cara Leahy, Marwan Sabbagh, Martin Sadowski, Curtis Schreiber, Paul E. Schulz, Jose Soria, David Weisman, Feride Frech, Daryl Rhys Jones
פורמט:	Artigo
שפה:	Inglês
יצא לאור:	Wiley 2026-04-01
סדרה:	Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
נושאים:	Alzheimer's disease (AD) anti‐amyloid monoclonal antibodies anti‐amyloid therapy (AAT) blood‐based biomarker (BBM) diagnosis lecanemab
גישה מקוונת:	https://doi.org/10.1002/dad2.70376
תגים:	הוספת תג אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!